Results 21 to 30 of about 249,494 (353)

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

Frontiers in Psychiatry, 2017
Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects.
Laura Orsolini, Laura Orsolini, Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Domenico De Berardis, Domenico De Berardis, Amira Guirguis, John Martin Corkery, Fabrizio Schifano   +9 more
doaj   +1 more source

The Psychonauts’ World of Cognitive Enhancers

Frontiers in Psychiatry, 2020
BackgroundThere is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders.
Flavia Napoletano, Flavia Napoletano, Fabrizio Schifano, John Martin Corkery, Amira Guirguis, Amira Guirguis, Davide Arillotta, Davide Arillotta, Caroline Zangani, Caroline Zangani, Alessandro Vento, Alessandro Vento, Alessandro Vento   +12 more
doaj   +1 more source

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

Pharmaceuticals, 2023
Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people.
Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, Fabrizio Schifano   +8 more
doaj   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment [PDF]

British Journal of Clinical Pharmacology, EarlyView.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
openalex   +2 more sources

Understanding the Opioid Epidemic through Pharmacovigilance Signals: an Analysis of Pharmacovigilance Datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS) over 10 Years

Emerging Trends in Drugs, Addictions, and Health
Introduction: In the past twenty years, the consumption of opioid medications has reached significant proportions, leading to the so-called opioid epidemic, characterized by cyclical waves of heroin use and the non-medical use of pharmaceutical opioids ...
S. Chiappini, R. Vickers-Smith, A. Guirguis, J. Corkery, G. Martinotti, D.R. Harris, F. Schifano   +6 more
doaj   +1 more source

The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective

Frontiers in Psychiatry, 2019
The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new synthetic drugs.
Laura Orsolini, Laura Orsolini, Laura Orsolini, Stefania Chiappini, Duccio Papanti, Domenico De Berardis, Domenico De Berardis, Domenico De Berardis, John M. Corkery, Fabrizio Schifano   +9 more
doaj   +1 more source

Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant

Frontiers in Psychiatry, 2021
Kratom or Mitragyna speciosa (Korth.) is an evergreen tree of the coffee family native to South-East Asia and Australasia. It is used by locals recreationally to induce stimulant and sedative effects and medically to soothe pain and opiate withdrawal ...
Alessandro E. Vento, Alessandro E. Vento, Simone de Persis, Sergio De Filippis, Fabrizio Schifano, Flavia Napoletano, John M. Corkery, Georgios D. Kotzalidis, Georgios D. Kotzalidis   +8 more
doaj   +1 more source

Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques

Pharmacy
Introduction: The designer benzodiazepine (DBZD) market continues to expand whilst evading regulatory controls. The widespread adoption of social media by pro-drug use communities encourages positive discussions around DBZD use/misuse, driving demand ...
Anthony Mullin, Mark Scott, Giorgia Vaccaro, Giuseppe Floresta, Davide Arillotta, Valeria Catalani, John M. Corkery, Jacqueline L. Stair, Fabrizio Schifano, Amira Guirguis   +9 more
doaj   +1 more source

Psychedelic Fauna for Psychonaut Hunters: A Mini-Review

Frontiers in Psychiatry, 2018
Currently different classes of psychoactive substances are easily available for abuse, including several hundred novel psychoactive substances (NPS).
Laura Orsolini, Laura Orsolini, Laura Orsolini, Michela Ciccarese, Duccio Papanti, Domenico De Berardis, Domenico De Berardis, Domenico De Berardis, Amira Guirguis, John M. Corkery, Fabrizio Schifano   +10 more
doaj   +1 more source

Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances

Brain Sciences, 2020
Objective: This survey aimed to explore knowledge and experience on novel psychoactive substances (NPS) of healthcare professionals (HCPs). The study also aimed to assess how HCPs would like to improve their knowledge of NPS.
Camille Ramos, Amira Guirguis, Nigel Smeeton, Hadar Zaman, Anna-Marie Felice, Stephanie Bancroft, Rosalind Gittins, Gill Hawksworth, John Martin Corkery, Fabrizio Schifano   +9 more
doaj   +1 more source